Multicentre clinical study on ceftizoxime sodium intravenous injection for treatment of respiratory and urinary tract infection

Objective To evaluate the efficacy and safety of ceftizoxime intravenous injection compared to cefotaxime. Methods A randomized ,comparative, open, multicentre trial was conducted the dose of ceftizoxime intravenous was 2-3 g, bid and the duration of treatment was 7-14 days; the dose of cefotaxime intravenous was 2-3 g, bid for 7-14 days too. The total number of final evaluated subjects was 123 including 62 subjects in ceftizoxime group and 61 subjects for cefotaxime treatment group. The bacterial evaluated subjects were 54 for ceftizoxime and 50 for cefotaxime. Results Clinical efficacy rate and bacterial eradication rate for ceftizoxime was 87.10% and 85.19%, respectively. Clinical efficacy rate and bacterial eradication rate for cefotaxime was separately 85.25% and 86.00%. The incidence of adverse reaction including whole clinical reactions and laboratory abnormalities was 6.06% for ceftizoxime group and 7.81 % for cefotaxime group. Conclusion The ceftizoxime had an excellent clinical efficacy and good safety profile in treating patients with moderate to severe degree bacterial infections.